NI201000132A - INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3. - Google Patents

INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.

Info

Publication number
NI201000132A
NI201000132A NI201000132A NI201000132A NI201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A
Authority
NI
Nicaragua
Prior art keywords
cxccr3
receptor inhibitors
chemokines receptor
benzosulfonamide
sulfamido
Prior art date
Application number
NI201000132A
Other languages
English (en)
Inventor
s thorpe David
Smrcina Martin
D Cabel Dagmar
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201000132A publication Critical patent/NI201000132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Abstract

Esta invención se dirige a un compuesto 3 - ( amido o sulfamido) - 4 - ( 4 - azinil sustituido ) benzamida o benzosulfonamida como se define en la presente memoria. El compuesto 3 - ( amido o sulfamido) - 4 - ( 4 - azinil sustituido ) benzamida o benzosulfonamida es útil como inhibidor del receptor de quimioquinas CxCR3, y para prevenir o tratar una enfermedad mediada por el receptor de quimioquinas CxCR3 o afecciones relacionadas con la misma en un paciente que lo necesite.
NI201000132A 2008-02-19 2010-07-29 INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3. NI201000132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
NI201000132A true NI201000132A (es) 2011-03-16

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000132A NI201000132A (es) 2008-02-19 2010-07-29 INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.

Country Status (25)

Country Link
US (1) US8268828B2 (es)
EP (1) EP2262784B1 (es)
JP (1) JP2011512412A (es)
KR (1) KR20100123835A (es)
CN (1) CN102007108A (es)
AR (1) AR070430A1 (es)
AU (1) AU2009215643A1 (es)
BR (1) BRPI0908815A2 (es)
CA (1) CA2715557A1 (es)
CL (1) CL2009000368A1 (es)
CO (1) CO6241113A2 (es)
CR (1) CR11604A (es)
DO (1) DOP2010000254A (es)
EC (1) ECSP10010409A (es)
IL (1) IL207597A0 (es)
MA (1) MA32191B1 (es)
MX (1) MX2010008397A (es)
NI (1) NI201000132A (es)
NZ (1) NZ587380A (es)
PE (1) PE20091576A1 (es)
RU (1) RU2010138577A (es)
SV (1) SV2010003648A (es)
TW (1) TW200948791A (es)
WO (1) WO2009105435A1 (es)
ZA (1) ZA201005314B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
US9181226B2 (en) * 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
ES2663972T3 (es) 2012-01-10 2018-04-17 Merck Patent Gmbh Derivados de benzamida como moduladores de la hormona folículo estimulante
JP6073931B2 (ja) 2012-02-02 2017-02-01 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ４−（ベンゾイミダゾール−２−イル）−チアゾール化合物及び関連するアザ誘導体
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
KR102496364B1 (ko) * 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
DK3245203T3 (en) 2015-01-15 2019-02-18 Idorsia Pharmaceuticals Ltd HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
JP7142675B2 (ja) * 2017-03-26 2022-09-27 武田薬品工業株式会社 Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719660A (en) 1969-06-13 1973-03-06 Takeda Chemical Industries Ltd 2-furfurylthioinosine-5'-phosphate compounds
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
WO2003101970A1 (en) 2002-06-03 2003-12-11 Smithkline Beecham Corporation Imidazolium cxcr3 inhibitors
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
CN101142209A (zh) 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
WO2006088919A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
WO2006088840A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
US20080312215A1 (en) * 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
WO2007047202A1 (en) 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
EP1957076A2 (en) 2005-11-29 2008-08-20 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
CA2646958A1 (en) 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
JP2009543782A (ja) 2006-07-14 2009-12-10 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有している新規の複素環置換ピペラジン化合物
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
TW200948791A (en) 2009-12-01
KR20100123835A (ko) 2010-11-25
WO2009105435A1 (en) 2009-08-27
PE20091576A1 (es) 2009-11-05
RU2010138577A (ru) 2012-03-27
AU2009215643A1 (en) 2009-08-27
US8268828B2 (en) 2012-09-18
IL207597A0 (en) 2010-12-30
BRPI0908815A2 (pt) 2019-09-24
DOP2010000254A (es) 2010-08-31
MA32191B1 (fr) 2011-04-01
US20100305088A1 (en) 2010-12-02
AR070430A1 (es) 2010-04-07
MX2010008397A (es) 2010-08-23
JP2011512412A (ja) 2011-04-21
CL2009000368A1 (es) 2009-06-26
CO6241113A2 (es) 2011-01-20
SV2010003648A (es) 2011-01-31
ZA201005314B (en) 2011-03-30
EP2262784B1 (en) 2014-04-16
CA2715557A1 (en) 2009-08-27
CR11604A (es) 2010-10-05
CN102007108A (zh) 2011-04-06
EP2262784A1 (en) 2010-12-22
NZ587380A (en) 2011-09-30
ECSP10010409A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
NI201000132A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
BR112012008677A2 (pt) compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon
CR20110103A (es) Heteroarilos sustituidos
CR20110100A (es) Nuevos derivados de sulfamida sustituida
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
GT200600046A (es) Terapia de combinacion
HN2005036256A (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
EA201170832A1 (ru) Пуриновые соединения
CR11290A (es) Derivados de ciclopropilamida
BRPI0906522A2 (pt) Sulfonamidas como antagonistas de orexina
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
HN2012001160A (es) Agonistas mglu2
CO6361943A2 (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
ES2377881T3 (es) Inhibidores de Glepp-1 en el tratamiento de trastornos autoinmunes y/o inflamatorios
UY31667A1 (es) Inhibidores del receptor de quimioquinas cxcr3